A Phase III, double blind, randomized study of Bevacizumab in combination with Carboplatin or Cisplatin + Etoposide + Atezolizumab compared with Carboplatin or Cisplatin + Etoposide + Atezolizumab in patients with untreated ES-SCLC

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 11 Jul 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Atezolizumab; Carboplatin; Cisplatin; Etoposide
Indications Small cell lung cancer
Focus Therapeutic Use
Acronyms BEAT-SC
Sponsors Chugai Pharmaceutical

Most Recent Events

04 Jun 2024 Primary endpoint (Progression free survival) has been met.
04 Jun 2024 Results assessing the primary analysis for progression-free survival (PFS) and the first interim analysis for overall survival (OS) from BEAT-SC were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
20 Dec 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight